Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 3, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually due to the
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 2, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 29, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified
View HTML
Toggle Summary ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer.
View HTML
Toggle Summary ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
With a Confirmed Overall Response Rate of 64% and Favorable Tolerability in Patients with High FRα Expression, Combination Demonstrates Encouraging Outcomes Relative to Available Regimens WALTHAM, Mass. --(BUSINESS WIRE)--May 29, 2020-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 20, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
View HTML
Toggle Summary ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting
Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs)
View HTML
Toggle Summary ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
Combination Demonstrates Promising Anti-Tumor Activity and Favorable Tolerability, with a Confirmed Overall Response Rate of >60% in Patients with High FRα Expression Results to be Presented in an Oral Session at ASCO 2020 Virtual Scientific Program WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming RBC Capital Markets Global Healthcare Virtual Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 6, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2020-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 30, 2020 the compensation committee of the Company’s Board of Directors granted
View HTML